ADIS LTD
Adis Ltd is a medical and pharmaceutical publishing company operating a portfolio of over 30 drug-focused peer-reviewed journals, drug safety newsletters, and drug review services. Operating as a subsidiary of Springer Nature, it serves pharmaceutical companies, academic researchers, healthcare practitioners, and institutional libraries globally.
- Company typePrivate
- Founded1970
- HeadquartersAuckland, New Zealand
- Headcount—
- GTM typeB2B
- OfferingDigital Commerce or Content
What ADIS LTD does
Adis Ltd is a medical and pharmaceutical publishing company specializing in drug-focused peer-reviewed journals, drug safety intelligence, and supporting publishing services. Founded in 1960 (per firmographic record; company history references 1970) and headquartered in Auckland, New Zealand with UK offices in London and Chester, Adis operates as a subsidiary of Springer Nature following its 2015 acquisition. The company's core product is a portfolio of over 30 peer-reviewed medical journals spanning all therapeutic areas, organized into three tiers: Adis Premier Journals (established titles with high Impact Factors and traditional subscription access), Adis Rapid+ Journals (open access titles with 2-week peer review and personalized concierge service), and Adis Open Access Journals (fully open access under CC BY-NC licensing). Specialized sub-brands include Adis Drug Reviews (definitive drug evaluations and Q&As), the Reactions Weekly drug safety newsletter (monitoring 8,000+ indexed titles), and Digital Features & Plain Language Summaries. The underlying technology stack centers on the Editorial Manager manuscript-tracking system for peer review workflow, with all content distributed via Springer Nature's SpringerLink platform to thousands of institutions worldwide.
Adis monetizes through multiple revenue streams: institutional subscriptions, article processing charges (APCs) for open access, paid VIP Service for accelerated 30-day publication, fees for digital features and enhancements, and the Reactions Weekly newsletter subscription. The primary customer segments are pharmaceutical and biotech companies (as funders and authors), academic medical researchers (as authors and readers), healthcare practitioners and decision-makers (as readers), and librarians/institutions managing journal subscriptions. Drug regulation and reimbursement professionals represent a secondary segment served by the Drug Safety and PharmacoEconomics titles. Go-to-market combines enterprise-level partnerships with pharmaceutical and biotech firms via the Springer Nature distribution network, community-led engagement through editorial boards of globally recognized experts, conference participation, and digital channels including social media, eTOC email alerts, podcasts, and conference presence. The company has no public revenue disclosure, no funding history, and operates as a non-independent division within Springer Nature.
ADIS LTD firmographics
Firmographics- Name
- ADIS LTD
- Legal name
- Adis Journals
- Website
- https://adis.com
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Short description
- Adis Ltd is a medical and pharmaceutical publishing company operating a portfolio of over 30 drug-focused peer-reviewed journals, drug safety newsletters, and drug review services. Operating as a subsidiary of Springer Nature, it serves pharmaceutical companies, academic researchers, healthcare practitioners, and institutional libraries globally.
- Ownership category
- akta.pro rank
ADIS LTD industry classification
Industry- Product category
- Medical Journal Publishing
- NAICS
- Periodical Publishers (51312), Newspaper, Periodical, Book, and Directory Publishers (5131)
- SIC
- Periodicals: Publishing Or Publishing & Printing (2721)
- akta.pro primary industry
- Medical Writing & Publications (Clinical/Safety/HEOR) (HLAGALAG)
- akta.pro secondary industries
- Academic & Scholarly Journals Publishing (Peer-Reviewed) (MPAJABAC), Medical & Clinical Reference (Physicians, Nursing, Allied Health) (EDAGAGAA)
Keywords
Where ADIS LTD is headquartered
LocationHeadquarters
- HQ city
- Auckland
- HQ country
- New Zealand
- HQ region
- Oceania
Offices3 records
Markets served
ADIS LTD business model
Business model- GTM type
- B2B
- Offering type
- Digital Commerce or Content
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Subscription Journal Publishing: Traditional subscription-based access to peer-reviewed medical journals across all therapeutic areas, available via Springer Nature platforms to thousands of institutions worldwide
- Open Access Publishing (Article Processing Charges): Authors pay article processing charges to make articles freely accessible immediately upon publication. Fully open access journals and OpenChoice options available across portfolio
- VIP Service Fees: Accelerated publication service with administrative fees for priority processing, submission to first decision in 15 days guaranteed, and publication in 30 days
- Digital Features and Enhancements: Fees for digital features (videos, podcasts, infographics) and plain language summaries submitted after manuscript acceptance
- Reactions Weekly Newsletter: Drug safety newsletter subscription monitoring developments across indexed journals and pharmaceutical industry sources
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Adis Premier Journals - Standard peer review with 4-6 week timeline |
| Hybrid | Pay-as-you-go | Adis Rapid+ Journals - Expedited publication with 2-week peer review |
| Other | Pay-as-you-go | VIP Service - Accelerated publication in 30 days |
| Unit Pricing | Pay-as-you-go | Digital Features and Plain Language Summaries |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
ADIS LTD product offering
Product offeringCore offering
Adis publishes a portfolio of more than 30 peer-reviewed medical journals focused on drugs, devices, diagnostics, and other therapeutic interventions, spanning all therapeutic areas. The company also publishes the Reactions Weekly drug safety newsletter, runs the Adis Drug Reviews program of clinically relevant drug evaluations, and offers premium author services including the VIP accelerated publication service and Digital Features enhancements, all distributed through the Springer Nature SpringerLink platform.
Product overview
Adis is a medical and pharmaceutical publishing company offering over 30 peer-reviewed journals organized into three main tiers: Premier Journals (established titles with strong metrics and traditional subscription options), Rapid+ Journals (open access with rapid publication timelines and personalized service), and Open Access Journals (fully open access titles). The portfolio includes specialized sub-brands such as Adis Drug Reviews (definitive drug evaluations, Q&As, and biosimilar briefs), the Reactions Weekly drug safety newsletter, and Digital Features & Plain Language Summaries (enhancements like videos, podcasts, infographics). All content is accessible via SpringerLink. Key services include the VIP Service (accelerated 30-day publication), Pre-Submission Enquiry Service, Article Metrics, SharedIt content sharing, and manuscript cascading options. Journals span therapeutic areas including cardiovascular, dermatology, diabetes, neurology, oncology, infectious diseases, pharmacoeconomics, and more, serving healthcare practitioners, researchers, pharmaceutical industry professionals, and decision-makers.
Differentiator
Problem solved
Functional benefit
Brands
- Reactions Weekly: A newsletter focused on drug safety that delivers concise summaries of the latest findings, regulatory updates, and safety reports from across the global pharmaceutical landscape.
- Adis Premier Journals
- Adis Rapid+ Journals
- Adis Open Access Journals
- Adis VIP Service
Quantifiable outcome
- Peer review turnaround in 2 weeks for Rapid+ Journals
- +4 more outcomes
Companies that use ADIS LTD
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles5 records
ADIS LTD technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration13 records
Feature5 records
ADIS LTD partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Springer NaturecoreAdis is part of Springer Nature group, leveraging the parent company's global content platforms, distribution network, and infrastructure. Adis journals are published by Springer Nature and available through SpringerLink to thousands of institutions worldwide. The relationship provides Adis with access to Springer Nature's global content platforms, superior search engine optimization, semantic linking, and institutional distribution network.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
ADIS LTD competitors and assessment
Company assessmentBroad incumbents
- Elsevier (RELX Group): Largest scientific, technical, and medical publisher with flagship drug/clinical titles (The Lancet, International Journal of Pharmaceutics). Directly competes with Adis for pharma authors and institutional subscription dollars.
- Springer Nature: Adis's parent company and the largest academic publisher globally. Comparable because Adis journals are hosted on SpringerLink and Springer Nature provides distribution, SEO, and institutional sales; overlapping portfolio in medical and life sciences publishing.
- Taylor & Francis (Informa): Large academic publisher with extensive pharmaceutical and clinical medicine journals. Comparable as a competing venue for drug-focused authors and as a Springer Nature competitor in the institutional 'big deal' market.
- SAGE Publications: Independent academic publisher with growing pharmaceutical and life sciences journal portfolio and open access initiatives. Comparable as a competing subscription+OA venue for medical and pharmaceutical authors.
- Wolters Kluwer Health: Medical publisher with deep pharma and clinical content (Lippincott, Ovid platform). Directly comparable in serving pharmaceutical professionals and clinicians through journals, databases, and pharmacovigilance-adjacent content.
Direct peers
- Wiley: Major publisher with strong pharmaceutical sciences portfolio (British Journal of Clinical Pharmacology, Journal of Clinical Pharmacy and Therapeutics) and open access transition strategy directly paralleling Adis's Premier/Rapid+/OA tiers.
- Karger Publishers: Independent medical and scientific publisher with strong clinical pharmacology and drug research titles. Closely comparable in niche pharmaceutical publishing with subscription+hybrid OA models.
- Mary Ann Liebert, Inc. Independent publisher focused on biotechnology, pharma, and clinical medicine journals (e.g., Genetic Engineering & Biotechnology News, Journal of Aerosol Medicine). Comparable as a niche pharma/biotech focused journal publisher competing for similar authors.
- Thieme Medical Publishers: Medical specialty publisher with pharmaceutical and clinical drug titles. Comparable in therapeutic-area journal publishing for clinicians and pharmaceutical professionals.
Emerging players
- BMJ (British Medical Journal Publishing Group): Medical publisher with growing drug evaluation and clinical pharmacology content. Comparable as a competing high-impact medical journal venue for pharmaceutical and clinical authors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ADIS LTD social profiles
Digital presenceADIS LTD compliance and trust
Trust signalCompliance1 record
ADIS LTD financial estimates
Financial estimateRevenue estimate
Valuation estimate
ADIS LTD leadership team
Management profileNumber of profiles
Profiles3 records
ADIS LTD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ADIS LTD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ADIS LTD
What does ADIS LTD do?
Adis publishes a portfolio of more than 30 peer-reviewed medical journals focused on drugs, devices, diagnostics, and other therapeutic interventions, spanning all therapeutic areas. The company also publishes the Reactions Weekly drug safety newsletter, runs the Adis Drug Reviews program of clinically relevant drug evaluations, and offers premium author services including the VIP accelerated publication service and Digital Features enhancements, all distributed through the Springer Nature SpringerLink platform.
When was ADIS LTD founded?
ADIS LTD was founded in 1970.
Where is ADIS LTD based?
ADIS LTD is headquartered in Auckland, New Zealand, in the Oceania region.
How does ADIS LTD make money?
Five revenue lines are on record. Subscription Journal Publishing is the primary driver. The others are open Access Publishing (Article Processing Charges), VIP Service Fees, digital Features and Enhancements and reactions Weekly Newsletter.
Who are ADIS LTD's main competitors?
Broad incumbents on record are Elsevier (RELX Group), Springer Nature, Taylor & Francis (Informa), SAGE Publications and Wolters Kluwer Health. Direct peers are Wiley, Karger Publishers, Mary Ann Liebert, Inc. and Thieme Medical Publishers. BMJ (British Medical Journal Publishing Group) is listed as an emerging player.
Does ADIS LTD have an API?
No public API is recorded for ADIS LTD.
What industry is ADIS LTD in?
ADIS LTD's product category is Medical Journal Publishing. Its primary akta.pro industry code is HLAGALAG, Medical Writing & Publications (Clinical/Safety/HEOR), with a secondary code of MPAJABAC, Academic & Scholarly Journals Publishing (Peer-Reviewed). Its NAICS code is 51312 and its SIC code is 2721.